TY - JOUR
T1 - Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors
T2 - An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines
AU - Singh, Simron
AU - Bergsland, Emily K.
AU - Card, Cynthia M.
AU - Hope, Thomas A.
AU - Kunz, Pamela L.
AU - Laidley, David T.
AU - Lawrence, Ben
AU - Leyden, Simone
AU - Metz, David C.
AU - Michael, Michael
AU - Modahl, Lucy E.
AU - Myrehaug, Sten
AU - Padda, Sukhmani K.
AU - Pommier, Rodney F.
AU - Ramirez, Robert A.
AU - Soulen, Michael
AU - Strosberg, Jonathan
AU - Sung, Arthur
AU - Thawer, Alia
AU - Wei, Benjamin
AU - Xu, Bin
AU - Segelov, Eva
N1 - Funding Information:
Disclosure: Dr. Singh reports receiving grants and personal fees from Novartis; grants from End Serono; personal fees from Ipsen outside of the submitted work. Dr. Bergsland reports receiving personal fees from UpToDate; grants from Merck and Novartis; and other fees from Hutchison MediPharma outside of the submitted work. Dr. Hope reports receiving other fees from Ipsen; personal fees and other fees from Curium outside of the submitted work. Dr. Kunz reports receiving grants and other fees from Advanced Accelerator Applications and Lexicon Pharmaceuticals; grants from Thermo Fisher Scientific, Ipsen, and Xencor outside of the submitted work. Dr. Laidley reports receiving grants and other fees from Ipsen and Novartis; other fees from Progenics and Nordic Nanovector outside of the submitted work. Dr. Metz reports receiving grants and personal fees from Ipsen and Advanced Accelerator Applications; nonfinancial support from Lexicon; grants from Medtronic outside of the submitted work. Dr. Myrehaug reports receiving grants from Ipsen, Novartis, and Advanced Accelerator Applications outside of the submitted work. Dr. Padda reports receiving grants from EpicentRx, Bayer, Boehringer Ingelheim, and Forty Seven Inc.; personal fees and other fees from Pfizer, AstraZeneca, G1 therapeutics, and AbbVie outside of the submitted work. Dr. Pommier reports receiving personal fees and other fees from Novartis; personal fees from Advanced Accelerator Applications and Lexicon outside of the submitted work. Dr. Ramirez reports receiving grants from Aadi Bioscience; grants and personal fees from Merck; personal fees from Curium, Advanced Accelerator Applications, AstraZeneca, Ipsen, Genetech, and Guardant outside of the submitted work. Dr. Soulen reports receiving grants and personal fees from Guerbet LLC and Sirtex Medical; grants from BTG International outside of the submitted work. Dr. Strosberg reports receiving personal fees from Novartis, Ipsen, and Lexicon outside of the submitted work. Dr. Thawer reports receiving personal fees from Novartis outside of the submitted work. The remaining authors declare no conflict of interest.
Funding Information:
Disclosure: Dr. Singh reports receiving grants and personal fees from Novartis; grants from End Serono; personal fees from Ipsen outside of the submitted work. Dr. Bergsland reports receiving personal fees from UpToDate; grants from Merck and Novartis ; and other fees from Hutchison MediPharma outside of the submitted work. Dr. Hope reports receiving other fees from Ipsen; personal fees and other fees from Curium outside of the submitted work. Dr. Kunz reports receiving grants and other fees from Advanced Accelerator Applications and Lexicon Pharmaceuticals; grants from Thermo Fisher Scientific , Ipsen , and Xencor outside of the submitted work. Dr. Laidley reports receiving grants and other fees from Ipsen and Novartis; other fees from Progenics and Nordic Nanovector outside of the submitted work. Dr. Metz reports receiving grants and personal fees from Ipsen and Advanced Accelerator Applications; nonfinancial support from Lexicon; grants from Medtronic outside of the submitted work. Dr. Myrehaug reports receiving grants from Ipsen , Novartis , and Advanced Accelerator Applications outside of the submitted work. Dr. Padda reports receiving grants from EpicentRx , Bayer , Boehringer Ingelheim , and Forty Seven Inc.; personal fees and other fees from Pfizer , AstraZeneca , G1 therapeutics, and AbbVie outside of the submitted work. Dr. Pommier reports receiving personal fees and other fees from Novartis; personal fees from Advanced Accelerator Applications and Lexicon outside of the submitted work. Dr. Ramirez reports receiving grants from Aadi Bioscience ; grants and personal fees from Merck; personal fees from Curium, Advanced Accelerator Applications, AstraZeneca, Ipsen, Genetech, and Guardant outside of the submitted work. Dr. Soulen reports receiving grants and personal fees from Guerbet LLC and Sirtex Medical; grants from BTG International outside of the submitted work. Dr. Strosberg reports receiving personal fees from Novartis, Ipsen, and Lexicon outside of the submitted work. Dr. Thawer reports receiving personal fees from Novartis outside of the submitted work. The remaining authors declare no conflict of interest.
Publisher Copyright:
© 2020
PY - 2020/10
Y1 - 2020/10
N2 - Lung neuroendocrine tumors (LNETs) are uncommon cancers, and there is a paucity of randomized evidence to guide practice. As a result, current guidelines from different neuroendocrine tumor societies vary considerably. There is a need to update and harmonize global consensus guidelines. This article reports the best practice guidelines produced by a collaboration between the Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society. We performed a formal endorsement and updating process of the 2015 European Neuroendocrine Tumor Society expert consensus article on LNET. A systematic review from January 2013 to October 2017 was conducted to procure the most recent evidence. The stepwise endorsement process involved experts from all major subspecialties, patients, and advocates. Guided by discussion of the most recent evidence, each statement from the European Neuroendocrine Tumor Society was either endorsed, modified, or removed. New consensus statements were added if appropriate. The search yielded 1109 new publications, of which 230 met the inclusion criteria. A total of 12 statements were endorsed, 22 statements were modified or updated, one was removed, and two were added. Critical answered questions for each topic in LNET were identified. Through the consensus process, guidelines for the management of patients with local and metastatic neuroendocrine tumors have been updated to include both recent evidence and practice changes relating to technological and definitional advances. The guidelines provide clear, evidence-based statements aimed at harmonizing the global approach to patients with LNETs, on the basis of the principles of person-centered and LNET-specific care. The importance of LNET-directed research and person-centered care throughout the diagnosis, treatment, and follow-up journey is emphasized along with directions for future collaborative research.
AB - Lung neuroendocrine tumors (LNETs) are uncommon cancers, and there is a paucity of randomized evidence to guide practice. As a result, current guidelines from different neuroendocrine tumor societies vary considerably. There is a need to update and harmonize global consensus guidelines. This article reports the best practice guidelines produced by a collaboration between the Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society. We performed a formal endorsement and updating process of the 2015 European Neuroendocrine Tumor Society expert consensus article on LNET. A systematic review from January 2013 to October 2017 was conducted to procure the most recent evidence. The stepwise endorsement process involved experts from all major subspecialties, patients, and advocates. Guided by discussion of the most recent evidence, each statement from the European Neuroendocrine Tumor Society was either endorsed, modified, or removed. New consensus statements were added if appropriate. The search yielded 1109 new publications, of which 230 met the inclusion criteria. A total of 12 statements were endorsed, 22 statements were modified or updated, one was removed, and two were added. Critical answered questions for each topic in LNET were identified. Through the consensus process, guidelines for the management of patients with local and metastatic neuroendocrine tumors have been updated to include both recent evidence and practice changes relating to technological and definitional advances. The guidelines provide clear, evidence-based statements aimed at harmonizing the global approach to patients with LNETs, on the basis of the principles of person-centered and LNET-specific care. The importance of LNET-directed research and person-centered care throughout the diagnosis, treatment, and follow-up journey is emphasized along with directions for future collaborative research.
KW - Bronchial neuroendocrine tumors/tumours
KW - Consensus statements
KW - Guidelines
KW - Lung carcinoids
KW - Lung neuroendocrine tumors/tumours
UR - http://www.scopus.com/inward/record.url?scp=85089459874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089459874&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2020.06.021
DO - 10.1016/j.jtho.2020.06.021
M3 - Review article
C2 - 32663527
AN - SCOPUS:85089459874
SN - 1556-0864
VL - 15
SP - 1577
EP - 1598
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 10
ER -